These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. [Long-term treatments for systemic sclerosis: what are the perspectives?]. Mouthon L; Agard C; Garcia De La Peña-Lefebvre P; Guillevin L Ann Med Interne (Paris); 2002 Jun; 153(4):265-75. PubMed ID: 12218893 [TBL] [Abstract][Full Text] [Related]
66. B cells in systemic sclerosis: a possible target for therapy. Bosello S; De Luca G; Tolusso B; Lama G; Angelucci C; Sica G; Ferraccioli G Autoimmun Rev; 2011 Aug; 10(10):624-30. PubMed ID: 21545850 [TBL] [Abstract][Full Text] [Related]
75. Novel therapeutic strategies in scleroderma. Denton CP; Black CM Curr Rheumatol Rep; 1999 Oct; 1(1):22-7. PubMed ID: 11123010 [TBL] [Abstract][Full Text] [Related]
76. Lipids and eicosanoids in fibrosis: emerging targets for therapy. Castelino FV Curr Opin Rheumatol; 2012 Nov; 24(6):649-55. PubMed ID: 22810365 [TBL] [Abstract][Full Text] [Related]
77. Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. Young A; Khanna D Curr Opin Rheumatol; 2015 May; 27(3):241-8. PubMed ID: 25775190 [TBL] [Abstract][Full Text] [Related]
78. Connective tissue diseases: Immunosuppressive therapy in SSc: what is the target? Boin F; Wigley F Nat Rev Rheumatol; 2009 Jul; 5(7):357-8. PubMed ID: 19568247 [No Abstract] [Full Text] [Related]
80. Are we too lenient with immunosuppression in severe cases of Systemic Sclerosis? Siegert E; Riemekasten G Rheumatology (Oxford); 2016 Oct; 55(10):1914-6. PubMed ID: 27330162 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]